home / stock / huge / huge news

HUGE News and Press, FSD Pharma Inc. From 02/07/23

Stock Information
Company Name: FSD Pharma Inc.
Stock Symbol: HUGE
Market: NASDAQ
Website: fsdpharma.com
Menu
HUGE HUGE Quote HUGE Short HUGE News HUGE Articles HUGE Message Board
Get HUGE Alerts

News, Short Squeeze, Breakout and More Instantly...
HUGE - FSD Pharma gains as Canada clears early-stage study for multiple sclerosis candidate

The shares of Canadian biotech FSD Pharma ( NASDAQ: HUGE ) rose for the fourth consecutive session on Tuesday after announcing that Canada greenlighted its Phase 1 trial for multiple sclerosis candidate LUCID-21-302. Issuing a No Objection Letter (NOL), Health Canada has granted the r...
HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received notification that it can move forward...

HUGE - FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that recruiting is underway for its phase 2 trial of FSD201 ...
HUGE - Recruiting Underway in FSD Pharma's Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announce...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is front and center in a recent InvestmentPitch Media Video. The video spotlighted FDS Pha...

HUGE - InvestmentPitch Media Video Discusses FSD Pharma's Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS

VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical T...
HUGE - FSD Pharma files for starting early stage trial of multiple sclerosis drug

FSD Pharma ( NASDAQ: HUGE ) said it submitted a clinical trial application (CTA) seeking to start a phase 1 trial of Lucid-MS to treat multiple sclerosis (MS). Lucid-MS is a first-in-class neuroprotective compound and in preclinical models has shown to prevent myelin degradation (...

HUGE - FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation

Company Seeking to Initiate Phase 1 Clinical Trial for its First-in-Class Multiple Sclerosis Drug Candidate FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio o...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Authorized Share Repurchase Program

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced a share repurchase program. The company’s board of directors approved...
Previous 10 Next 10